Article citationsMore>>

Testori, A., Richards, J., Whitman, E., Mann, G.B., Lutzky J, Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J.M., Hoos, A., et al. (2008) Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: The C-100-21 Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 955-962. doi:10.1200/JCO.2007.11.9941

has been cited by the following article:

• TITLE: CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes

  AUTHORS: Luis E. Raez, Gail R. Walker, Paulette Baldie, Eva Fisher, Jorge E. Gomez, Khaled Tolba, Edgardo S. Santos, Eckhard R. Podack

  KEYWORDS: Heat Shock Protein; Chaperone Gp-96; Non-Small Cell Lung Cancer; Gene Transfer Immunotherapy; Allogeneic Vaccine; Cytotoxic CD8 T Cells

  JOURNAL NAME: Advances in Lung Cancer, Vol.2 No.1, March 21, 2013

  ABSTRACT: Antigen containing, allogeneic cells secreting the genetically modified protein and peptide-chaperone gp96-Ig cross, prime and expand antigen specific CD8 T cells with therapeutic antitumor activity in mice. In a first in man phase I study, we now report the results of therapeutic vaccination of non-small cell lung cancer (NSCLC) patients with an established, allogeneic non-small cell lung adenocarcinoma cell line secreting gp96-Ig. Advanced NSCLC-patients stage IIIB or IV of any histological subtype were enrolled and treated with up to 36 vaccinations over the course of 18 weeks. Primary endpoint was safety, secondary endpoints tumor response and overall survival. Measurement of tumor antigen specific CD8 CTL responses is precluded by the lack of known NSCLC associated antigens. Therefore, we measured patient CD8 T cell-IFN-γ responses to allo-antigens of the vaccine cells as surrogate for tumor antigen specific CD8 CTL. In 7 of 18 treated patients tumor growth was stabilized, however none of the 18 patients had an objective tumor response by RECIST criteria. Of 15 patients evaluable for immune response, 11 responded to vaccination with more than twofold increase in CD8-IFN-γ frequency above baseline. These patients had a median survival time of 16.5 months. Four patients who had no CD8 response above base line had survival times from 2.1 to 6.7 months. Our data are consistent with the concept that generation of CD8 CTL by therapeutic vaccination may delay tumor growth and progression and mediate prolonged survival even in the absence of objective tumor responses. Further studies will be required to test this concept and promising result.